Skip to main content
SpringerLink
Log in

Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer

  • Article
  • Published:
Pathology & Oncology Research

Abstract

The expression of several genes involved in the regulation of cell cycle and apoptosis may be regulated via the androgen receptor (AR) in the prostate. AR may have a role in the prognosis of prostatic carcinoma. The aim was to examine AR expression status and its relationship with markers of proliferation, apoptosis and cell cycle control in prostate cancer. Expression of AR, bcl-2, bax, Ki-67 and p53 was examined in paraffin-embedded tissues from 50 cases of prostate carcinoma by immunohistochemistry and evaluated using an index of staining. Detection of apoptotic cells was performed by TUNEL method. Correlation between AR expression and apoptosis, proliferation index, bcl-2, bax and p53 and also clinicopathological parameters including stage, pathological grade and Gleason score were determined. AR expression was observed in all cases with mean expression of 81%±15 and mean staining index of 141±65. No correlation was found between AR expression and apoptosis detected in patients. The mean AR staining index was 170±72 in bcl-2 positive tumors versus 120±53 in bcl-2 negative tumors showing a significant association between AR and bcl-2 expression (p=0.015). AR expression also showed a significant association with bcl-2/bax ratio (r=0.321, p=0.023) and Ki-67 proliferation staining index (r=0.396, p=0.004). Although a significant correlation between Ki-67 and p53 with differentiation status of the tumors was observed (p<0.004) no correlation was found with AR. AR expression showed no prognostic value regarding its correlation with stage and differentiation status of the prostate carcinoma. However, its significant correlation with Ki-67 and bcl-2 that are markers of cell survival suggest its contribution to tumor cell progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Buttyan R, Shabsigh A, Perlman H, Colombel M. Regulation of Apoptosis in the Prostate Gland by Androgenic Steroids. Trends Endocrinol Metab 10:47–54, 1999

    Article  PubMed  CAS  Google Scholar 

  2. Chang C, Saltzman A, Yeh S et al.: Androgen receptor: an overview. Crit Rev Eukaryot Gene Exp 5: 97–125, 1995

    CAS  Google Scholar 

  3. Eder IE, Culig Z, Putz T et al.: Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol 40:241–51, 2001

    Article  PubMed  CAS  Google Scholar 

  4. Klocker H, Culig Z, Eder IE et al: Mechanism of androgen receptor activation and possible implications for chemoprevention trials. Eur Urol 35: 413–419, 1999.

    Article  PubMed  CAS  Google Scholar 

  5. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552–562, 1988

    Article  PubMed  CAS  Google Scholar 

  6. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 20: 3001–3015, 2002

    Article  PubMed  CAS  Google Scholar 

  7. Feng Z, Joos HJ, Vallan C et al: Apoptosis during castrationinduced regression of the prostate is Fos dependent. Oncogene 19: 17: 2593–600, 1998

    Article  CAS  Google Scholar 

  8. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 168: 9–12, 2002

    Article  PubMed  Google Scholar 

  9. Culig Z, Klocker H, Bartsch G et al: Androgen receptors in prostate cancer. J Urol 170: 1363–1369 2003.

    Article  PubMed  CAS  Google Scholar 

  10. Culig Z, Hobisch A, Erdel M et al: Studies on androgen receptor mutations and amplification in human prostatecancer. Methods Mol Med 81: 267–275, 2003

    PubMed  CAS  Google Scholar 

  11. Sadi MV, Barrack ER: Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 15: 71: 2574–2580, 1993

    Article  Google Scholar 

  12. Miyamoto KK, McSherry SA, Dent GA et al.: Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 149:1015–1019, 1993

    PubMed  CAS  Google Scholar 

  13. de Winter JA, Trapman J, Brinkmann AO et al: Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol 160: 329–332, 1990

    Article  PubMed  Google Scholar 

  14. Shaffer DR, Scher HI. Prostate cancer: a dynamic illness with shifting targets. Lancet Oncol 4: 407–414, 2003

    Article  PubMed  Google Scholar 

  15. Magi-Galluzzi C, Xu X, Hlatky L et al: Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol 10: 839–845, 1997

    PubMed  CAS  Google Scholar 

  16. Sweat SD, Pacelli A, Bergstralh EJ et al: Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol 161: 1229–1232, 1999

    Article  PubMed  CAS  Google Scholar 

  17. Yoshikawa H, Ikeuchi T, Kai Y. Immunohistochemical study of androgen receptor in adenocarcinoma of the human prostatic cancer. Nippon Hinyokika Gakkai Zasshi 87: 956–963, 1996

    PubMed  CAS  Google Scholar 

  18. van der Kwast TH, Schalken J, Ruizeveld de Winter JA et al: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48: 189–193, 1991

    Article  PubMed  Google Scholar 

  19. Takeda H, Akakura K, Masai M et al.: Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 77: 934–940, 1996

    Article  PubMed  CAS  Google Scholar 

  20. Finnegan NM, Curtin JF, Prevost G et al: Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br J Cancer 85: 115–121, 2001

    Article  PubMed  CAS  Google Scholar 

  21. DiPaola RS, Aisner J. Overcoming bcl-2- and p53-mediated resistance in prostate cancer. Semin Oncol 26(Suppl) 2: 112–116, 1999

    PubMed  CAS  Google Scholar 

  22. Kolar Z, Murray PG, Madarova J et al: Nuclear receptors in early hormone refractory prostate cancer and their relationship to apoptosis-related proteins. Neoplasma 49:172–177, 2002

    PubMed  CAS  Google Scholar 

  23. Fizazi K, Martinez LA, Sikes CR et al: The association of p21 (WAF-1/CIP1) with progression to androgen-independent prostate cancer. Clin Cancer Res 8: 775–781, 2002

    PubMed  CAS  Google Scholar 

  24. Tanji N. Yokoyama M. Sagamoto T et al: Apoptosis in prostatic adenocarcinoma; A study of relationship to Ki-67 and bcl-2 protein expression. Anticancer Res 18:1111–1116, 1998

    PubMed  CAS  Google Scholar 

  25. Kaltz-Wittmer C, Klenk U, Glaessgen A et al: FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 80: 1455–1464, 2000

    PubMed  CAS  Google Scholar 

  26. Baretton GB, Klenk U, Diebold J et al: Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80: 546–555, 1999

    Article  PubMed  CAS  Google Scholar 

  27. Cadwell C, Zambetti GP: The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 17: 15–30, 2001

    Article  Google Scholar 

  28. Brooks JD, Bova GS, Ewing CM et al: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56: 3814–3822. 1996

    PubMed  CAS  Google Scholar 

  29. Navone NM, Troncoso P, Pisters LL, et al.: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657–1669, 1993

    Article  PubMed  CAS  Google Scholar 

  30. Aprikian AG, Sarkis AS, Fair WR et al: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 151: 1276–1280, 1994

    PubMed  CAS  Google Scholar 

  31. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14: 86–91, 2002

    Article  PubMed  CAS  Google Scholar 

  32. Howell SB. Resistance to apoptosis in prostate cancer cells. Mol Urol 4: 225–229, 2000

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Medical School, Shiraz University of Medical Science, Shiraz, Iran

    Ahmad Monabati

  2. Department of Pathology, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

    Zahra Amirghofran, Ahmad Monabati & Naser Gholijani

Authors
  1. Zahra Amirghofran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmad Monabati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naser Gholijani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zahra Amirghofran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amirghofran, Z., Monabati, A. & Gholijani, N. Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer. Pathol. Oncol. Res. 10, 37–41 (2004). https://doi.org/10.1007/BF02893407

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02893407

Keywords

Search

Navigation